Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

in Ann Arbor, Michigan, and the Mayo Clinic in Rochester, Minnesota.

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the

meaning of Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements, including the Company's expectations

related to the U.S. Phase II sarcoma clinical trial and the Company's

belief as to the potential of REOLYSIN(R) as a cancer therapeutic,

involve known and unknown risks and uncertainties, which could cause the

Company's ac
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... the last decade, the laboratory filtration market is experiencing ... acceptance of new filtration technologies in end users market. ... catalyzing the growth of laboratory filtration market. , The ... a strong CAGR during the forecast period of 2014-2019 ... 2019. The market is mainly driven by the increasing ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
(Date:9/30/2014)... 30, 2014 Genedata, a ... drug discovery and related life science research, ... chosen Genedata Selector as its host-pathogen data ... FUNGITECT is a European consortium dedicated to ... via individualized anti-fungal drug therapies. Genedata Selector ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... For Women in Science program is welcoming the 15 International Fellows ... , On Wednesday, March 28, from 4 pm to ... the Pasteur Institute in Paris. Following these presentations, a cocktail ... be met individually , , On ...
... physics of massive particles has intrigued physicists for more than ... exhibit wave-like behaviour in conflict with our everyday ideas ... of scientists now succeeded in shooting a movie which shows ... molecules which is so large (up to 0.1 mm) that ...
... March 22, 2012 /PRNewswire-iReach/ -- FirstMark, the ... announce that the company will be exhibiting at the ... College of Cardiology (ACC) in Chicago, March 24-27, Booth ... PREvent is the first and only multiple biomarker blood ...
Cached Biology Technology:The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 2The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 3The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 4Single molecules in a quantum movie 2FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo 2
(Date:9/30/2014)... new research, involving mice and published in the October ... Biology , suggests that just because you can ... a team of Italian scientists have found that using ... the immune system. This damage may result in autoimmune ... inflammatory bowel disease and rheumatoid arthritis in adulthood. , ...
(Date:9/30/2014)... trouble getting pregnanteven with IVF? Here,s some hope: A ... The FASEB Journal , explains how ... known as PAWP, which induced embryo development in human ... embryo development by the sperm cell during fertilization. , ... a major paradigm shift in our understanding of human ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... selected 20 project proposals across Africa to receive support ... cycle and to improve water-monitoring resources. TIGER II ... precursor TIGER I, which sought to help African countries ... gap using Earth-observation (EO) technology. ,Under TIGER ...
... University research team has demonstrated that all sweeteners are not ... to high-fructose corn syrup gained significantly more weight than those ... intake was the same. In addition to ... high-fructose corn syrup also led to abnormal increases in body ...
... cells responsible for immune surveillance in the brain, and ... damage and infection. An international team under the leadership ... that these cells may actually make a significant contribution ... About 1.2 million people are thought to suffer from ...
Cached Biology News:ESA's TIGER II to support 20 water projects in Africa 2ESA's TIGER II to support 20 water projects in Africa 3Princeton researchers find that high-fructose corn syrup prompts considerably more weight gain 2Princeton researchers find that high-fructose corn syrup prompts considerably more weight gain 3Princeton researchers find that high-fructose corn syrup prompts considerably more weight gain 4Dangerous custodians 2
Request Info...
with GlutaMAXIL-glutamine...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Biology Products: